Clinical efficacy observation of fludarabine combined with cyclophophamide and methylprednisolone in chronic lymphocytic leukemia patients

方志坚,余延芳,王明迪,李德津,高美娟

DOI: https://doi.org/10.3969/j.issn.1671-4695.2013.08.007

2013-01-01

Abstract:Objective To evaluate the therapeutic effects and adverse reactions of fludarabine combined with cyclophophamide and methylprednisolone for treatment of chronic lymphocytic leukemia(CLL) patients.Methods Twenty-five patients with CLL were included into this study.Fourteen of these patients did not have previous treatment.Eleven of these patients were relapsed or refractory case.These patients were treated with FCM regiment,including fludarabine 50 mg/d,iv,day 1to 3;cyclophophamide 300 mg/d,iv,day 1 to 3;and methylprednisolone 40 mg/d,iv,day 1 to 5.Twenty eight to thirty days was a treatment cycle(for 1 cycle).This cycle was repeated for total 4-6 cycles.Results Twenty five patients completed about 4.9 cycles.Complete response(CR) rate was 64%.Partial response(PR) rate was 28% and overall respose(OR) rate was 92 %.In previously untreated group,CR rate was 78.6%,PR rate was 21.4%,OR rate was 100 % compared to the relapsed or refractory group with CR rate of 45.5 %,PR rate of 36.4 % and OR rate of 81.9%.There was no significant difference of CR and OR rate between the two groups(P>0.05).The main side effects were myelosuppression and infection,which are within the tolerance range.Other adverse reactions included nausea,vomiting,mild liver and kidney dysfunction,elevated blood sugar,which can return to normal after treatment.Conclusion FCM regiment has a positive therapeutic effect and few adverse reaction,which can be used as the preferred solution for the treatment of CLL.